ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Polymyxin B

Also written as “Polymyxin B (50 mg)” and “polymyxin B sulphate + prednisolone + benzocaine + clioquinol”.

Its studies are mostly in Pneumonia, Bacterial · Eczema, led by 3 companies.

Drug pagePolymyxin B: every studyAll 11 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Jan 7, 20264 company-led studies, 2 open or runningNext primary completion: Dec 30, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
BioVersys SAS22 open or runningphase 3since Jan 7, 2026Jan 7, 2026Dec 30, 2027phase 3 · NCT07326540
EMSits history only10 open or runningphase 3since Sep 5, 2011Sep 5, 2011none ahead
TTY Biopharmits history only10 open or runningphase 1since Mar 29, 2022Mar 29, 2022none ahead

Also a collaborator on its studies: BioVersys.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of BioVersys SAS only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jan 7, 2026First study: phase 3 study in Hospital Acquired Bacterial Pneumonia (HABP)First studyNCT07326540 · 248 planned · Georgia
  2. Apr 28, 2026Phase 1 study in Healthy Adult ParticipantsNCT07580586 · 16 planned · Austria

Ahead

  1. Dec 30, 2027Primary completion: phase 3 study in Hospital Acquired Bacterial Pneumonia (HABP)NCT07326540

TargetBeta

A vaccine: it acts on a pathogen, not a human gene.

“Cell outer membrane inhibitor”ChEMBL 37, by rule

Studies

All 2 BioVersys SAS leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07580586Healthy Adult Participants · Austria1RecruitingSep 30, 202616
NCT07326540Hospital Acquired Bacterial Pneumonia (HABP) · Georgia3RecruitingDec 30, 2027248

How it is read

Names in the registry

  • “Polymyxin B”, 2 entries
  • “Polymyxin B (50 mg)”, 1 entry
  • “polymyxin B sulphate + prednisolone + benzocaine + clioquinol”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.